These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 26949069)
21. [Importance of dyslipidaemia in cardiovascular disease: a point of view]. Ascaso JF; Carmena R Clin Investig Arterioscler; 2015; 27(6):301-8. PubMed ID: 26363575 [TBL] [Abstract][Full Text] [Related]
22. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
23. [Atherogenic dyslipidemia and residual risk. State of the art in 2014]. Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X; Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326 [TBL] [Abstract][Full Text] [Related]
24. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management. de Nijs T; Sniderman A; de Graaf J Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059 [TBL] [Abstract][Full Text] [Related]
25. Non-HDL cholesterol as a therapeutic goal. Brea A; Hernández-Mijares A; Millán J; Ascaso JF; Blasco M; Díaz A; Mantilla T; Pedro-Botet JC; Pintó X Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():28-33. PubMed ID: 31806265 [TBL] [Abstract][Full Text] [Related]
27. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines]. Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR; Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438 [TBL] [Abstract][Full Text] [Related]
31. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506 [TBL] [Abstract][Full Text] [Related]
32. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668 [TBL] [Abstract][Full Text] [Related]
33. Atherogenic dyslipidemia: prevalence and management in lipid clinics. Pedro-Botet J; Flores-Le Roux JA; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Rev Clin Esp (Barc); 2014 Dec; 214(9):491-8. PubMed ID: 25016414 [TBL] [Abstract][Full Text] [Related]
34. Urban-rural differences in atherogenic dyslipidaemia (URDAD Study): a retrospective report on diabetic and non-diabetic subjects of Northern India. Agrawal P; Reddy VS; Madaan H; Patra SK; Garg R J Health Popul Nutr; 2014 Sep; 32(3):494-502. PubMed ID: 25395912 [TBL] [Abstract][Full Text] [Related]
35. Management of atherogenic dyslipidemia in the primary care setting in Spain. Díaz Rodríguez Á; Blasco Valle M; Mantilla Morató T; Capón Alvarez J; Rodríguez de Miguel M; Rodríguez-Fortúnez P; Prada-Marcos C; Orera-Peña ML Clin Investig Arterioscler; 2019; 31(5):203-209. PubMed ID: 31320121 [TBL] [Abstract][Full Text] [Related]
36. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108 [TBL] [Abstract][Full Text] [Related]
37. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Windler E; Schöffauer M; Zyriax BC Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442 [TBL] [Abstract][Full Text] [Related]
39. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. Tournadre A; Pereira B; Dubost JJ; Rincheval N; Rat AC; Combe B; Soubrier M Clin Exp Rheumatol; 2017; 35(2):296-302. PubMed ID: 28079508 [TBL] [Abstract][Full Text] [Related]
40. Control of the overall lipid profile. Blasco M; Ascaso JF; Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():34-41. PubMed ID: 31785850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]